Drug Type Peptide Conjugate Radionuclide, Diagnostic radiopharmaceuticals |
Synonyms- |
Target |
Action modulators |
Mechanism PSMA modulators(Prostate-specific membrane antigen modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhaseClinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Prostatic Cancer | Clinical | Germany | 19 Jul 2019 |
Not Applicable | prostate-specific antigen | 54 | 18F-JK-PSMA-07 (PSMA PET/CT) | wllsjmppfh(leafaofogh) = xiszanbcvx hijewexwbx (prbirowuhu ) | - | 27 Sep 2024 | |
18F-JK-PSMA-07 (PSA>1 ng/ml) | ndwiaqtfnx(ahxdzwxvst) = apikbpaitb kjdionjqie (lmavysrruf ) | ||||||
Not Applicable | Non-metastatic prostate cancer prostate-specific antigen | 30 | 18 F-JK-PSMA-07 (PSMA PET/CT Scan) | zxklyygxql(dmlcqqszih) = qpbzidqlto qlmbvrykkm (ougabiquug ) View more | - | 22 Sep 2022 |